ACV meeting #33, 20 May 2022

The meeting of the Advisory Committee on Vaccines (ACV).

The committee provided advice on two applications:

• Major variation (booster dose for individuals aged 12 years and over) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Spikevax; active ingredient elasomeran [mRNA]; sponsor Moderna Australia Pty Ltd) that had been under evaluation from March 2022
• Major variation (booster dose for individuals aged 18 years and over) for a vaccine with provisional registration for active immunisation to prevent COVID-19 (product name Nuvaxovid; active ingredient SARS-CoV-2 rS with Matrix-M adjuvant; sponsor Biocelect Pty Ltd) that had been under evaluation from March 2022.

Members

Membership comprises professionals with expertise in specific scientific, medical or clinical fields, or consumer health issues.